Scarica l'app Stockscreener
13.08
1.51%
-0.20
Dopo l'orario di chiusura:
13.34
0.26
+1.99%
Generate Biomedicines Inc Borsa (GENB) Ultime notizie
GENB News Today | Why did Generate Biomedicines stock go down today? - MarketBeat
Working capital per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
Generate Biomedicines (GENB) 10K Form and SEC Filings 2026 - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Return on assets % of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Goodwin Advises Generate Biomedicines, Inc. On The Closing Of Its $400 Million Initial Public Offering - Mondaq
Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Generate Biomedicines IPO Opens Nasdaq Chapter And Investor Watch Period - simplywall.st
GENB Stock Price, News & Analysis - Stock Titan
Generate Biomedicines, Inc. Cash Flow – BOATS:GENB - TradingView
Generate Biomedicines, Inc. Income Statement – BOATS:GENB - TradingView
Generate Biomedicines, Inc. (GENB) Stock Live Price, Chart & News - CoinCodex
GENB PE Ratio & Valuation, Is GENB Overvalued - Intellectia AI
GENB | Generate Biomedicines, Inc. Common Institutional Ownership - Quiver Quantitative
GENB | Generate Biomedicines, Inc. Common Insider Trading - Quiver Quantitative
Insider Buying: Jane Mendillo Acquires Shares in Generate Biomed - GuruFocus
GENB: Static price chart | Generate Biomedicines, Inc. | US3709201004 - marketscreener.com
Assessing Generate Biomedicines (GENB) Valuation After Recent Share Price Volatility - Sahm
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO By Investing.com - Investing.com UK
Executive at Generate Biomedicines (GENB) awarded 190,034 stock options - Stock Titan
Generate Biomedicines (GENB) CEO adds options and IPO conversion shares - Stock Titan
Director at Generate Biomedicines (GENB) buys stock and receives 29,561 options - Stock Titan
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO - Investing.com
Governance revamp at Generate Biomedicines (NASDAQ: GENB) after IPO - Stock Titan
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug - Dealbreaker
Generate IPO raises $400 million but shares sink - The Pharma Letter
Generate Biomedicines (GENB) CMO awarded 42,230 stock options vesting over 4 years - Stock Titan
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to NASDAQ Composite Index - marketscreener.com
EBITDA of GENERATE BIOMEDICINES INC – NASDAQ:GENB - TradingView
Generate Biomedicines shares fall in weak Nasdaq debut for drug developer - WSAU
Generate Biomedicines prices IPO at $16 per share By Investing.com - Investing.com Australia
Generate Biomedicines Shares Plummet After $400 Million Market Debut - WSJ
U.S. IPO Weekly Recap: Asthma-Focused Generate Biomedicines Closes Out February IPO Market - Seeking Alpha
IPO NewsUS IPO Weekly Recap: Asthma-focused Generate Biomedicines closes out February IPO market - renaissancecapital.com
AI-Focused Generate Biomedicines Prices $400M IPO - Law360
Generate Biomedicines, AI-Driven Generative Biology Drug Developer, Files for Nasdaq Global Select Market IPO - TradingView
Generate Biomedicines Share Price Target and Forecast - Investing.com India
Generate Biomedicines stock opens below IPO price in Nasdaq debut By Investing.com - Investing.com South Africa
Generate Biomedicines stock opens below IPO price in Nasdaq debut - Investing.com
Generate Biomedicines Shares Fall After Nasdaq Debut - marketscreener.com
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut - AOL.com
Generate Biomedicines-Aktien fallen bei schwachem Nasdaq-Debüt des Arzneimittelentwicklers - TradingView
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer - TradingView
Shares of Generate Biomedicines open at $15 in their Nasdaq debut vs $16 IPO price - marketscreener.com
TSLP still plays well, Generates $400M IPO - BioWorld MedTech
Generate Biomedicines, Inc. share price - Capital.com
AI-driven drug developer nets $400M IPO, matching 2020 record - The Business Journals
Generate’s $400m IPO Adds To Biotech Bounceback - Citeline News & Insights
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
Trade Generate Biomedicines, Inc.GENB CFD - Capital.com
Generate:Biomedicines Rings the Nasdaq Stock Market Opening Bell - Nasdaq
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):